View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 6, 2020updated 11 Jul 2022 9:54am

Coronavirus: Bioxytran’s BXT-25 may treat ARDS patients

US-based biotechnology company Bioxytran has announced plans to develop its investigational candidate, BXT-25, to treat late-stage patients infected with the new coronavirus who have acute respiratory distress syndrome (ARDS).

Follow the latest updates of the outbreak on our timeline.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

US-based biotechnology company Bioxytran has announced plans to develop its investigational candidate, BXT-25, to treat late-stage patients infected with the new coronavirus who have acute respiratory distress syndrome (ARDS).

According to the company, most late-stage coronavirus patients developed ARDS during the ongoing outbreak.

The company is seeking partners to develop its drug candidate as a treatment for ARDS, which occurs due to low blood oxygen levels caused by the buildup of fluids in the lungs.

ARDS is commonly treated with oxygen therapy and ventilator support, while diuretics are given to increase urination for regulating fluid levels and preventing a buildup of fluids.

Originally intended to treat hypoxia, BXT-25 is designed to transport oxygen in the body by receiving oxygen from the lungs, delivering it to organs and tissues throughout the body.

The treatment will allegedly offer enough time for the patient to recover and, over time, the body’s immune system will destroy the virus.

The company adds that its MDX Viewer can allow remote monitoring and measure the tissue metabolic score, which could predict organ failure.

A diagnostic for oxygen consumption of the organs is expected to help triage patients and perform clinical trials of drugs in real-time.

Bioxytran CEO David Platt said: “This could be a major advancement in the treatment of end-stage patients infected with the Wuhan Coronavirus.

“The primary reason the coronavirus is so lethal is that the body fails to deliver oxygen.  This is such a fundamental concept that we feel confident that we will be successful partnering for the ARDS due to the Wuhan Coronavirus indication.”

The company expects that the drug candidate will not have any side effects.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology